Neurona's neural cell therapies have single-dose curative potential. Based on a novel neural cell lineage pioneered by the company's scientific founders, Neurona has built a robust regenerative platform and is developing neuronal, glial, and gene-edited cell therapy candidates that provide long-term repair of dysfunctional neural networks for multiple neurological disorders.
Date | Amount | Type | Investors | Valuation |
---|---|---|---|---|
06/22/21 | $41,500,000 | Venture |
Alexandria Venture Investments Ironfire Ventures Sphera Funds Management The Column Group ![]() UCB Ventures ![]() | undisclosed |
02/08/24 | $120,000,000 | Venture |
Alexandria Venture Investments Berkeley Frontier Fund Cormorant Asset Management ![]() Euclidean Capital LYFE Capital Schroders Capital Sphera Funds Management Spur Capital Partners Symbiosis The Column Group UC Investments UCB Ventures Viking Global Investors ![]() Willett Advisors Ysios Capital | undisclosed |